This year's list of the top 10 "prey" for medical acquisitions: BMS and Biogen

　　Last year, the pharmaceutical industry traded more than $200 billion, roughly the same as the previous two years, according to data from ernst & young.HBMPartners company data show, however, the global biopharmaceutical industry deals last year fell 35% year on year, from 2015, the company estimates of $228.1 billion to $2016 in 148.2 billion.Zephyr biotechnology report listed trading gross decline is more apparent, according to the statistics, the pharmaceutical industry trade totaled $2016 in 94.62 billion, less than $2015 in 121.294 billion.Research by deloitte shows that the value of the pharmaceutical industry fell from $118bn in 2015 to $91bn in 2016.Although the agencies' statistics are inconsistent, there is a general trend in which m&a activity in the pharmaceutical industry has been curbed in 2016.

　　President promised to reduce trump public expenditures in medication, the expected by publishing marketization mechanism and more friendly to industry policy to achieve this goal., for instance, allow Medicaid (Medicaid) and a health insurance program (Medicare) and drug developers, price negotiations, the United States enterprise backflow offshore funds rate from 35% to 10%.Ernst & young has pointed out that such a policy could lead to a much higher level of m&a in the pharmaceutical sector this year than last year.

　　The m&a market is expected to be more popular for quite a few enterprises may be acquired by the close attention and discussion, a few days ago, GEN website "prey" list released ten m&a.Compared with last year, there are six new faces in this year's list.For every company on the list, GEN explains where the acquisition rumours come from and why it is a takeover target.

　　As in the past few years,small and medium-sized market value of biopharmaceutical company is still the life of the merger and acquisition activity, because of its in new drug approvals, new indications of clinical research project success to expand sales, is expected to add billions of dollars in sales) showed good prospects.

　　1,Biogen

　　Slimming is more attractive

　　Biogen has taken a series of actions (most of which have been popular with investors) since the discovery of its own takeover rumours.Last August, the Wall Street journal reported that it had attracted interest from Merck and Allergan as a potential acquisition target.

　　Since then, the company has spun off its hemophilia and other rare blood disease businesses into a new company called Bioverativ.Market analysts say the move could make it a more attractive takeover target.In a survey of market analysts by EvercoreISI, it emerged as one of the top three major biopharmaceuticals companies to be bought.

　　Stripping Bioverativ makes the best health to focus on treatment of eye disease and neural system disease, such as for spinal muscle atrophy of the first treatment is developed by the national health Spinraza (nusinersen), the drug approved by the FDA listed in December.

　　Biogen become targets of another reason is that the drug to the management of multiple sclerosis (MS) in a leading position in the market, the main product Tecfidera generated sales of $3.968 billion last year, up 9% from 2015.Another MS drug, Plegridy (polyethylene glycol interferon beta-1a), saw its sales rise 42% year-on-year to $482 million in 2016.In 2016, the company's net income reached us $37.03 billion, up 4% from a year earlier, to $11.449 billion.

　　2, BioMarin

　　Product line growth is strong

　　Without BioMarin, the target list would be a lot worse.Since GEN first published the list in 2013, BioMarin, a rare drug developer, has been included in the list.In 2013, the market was rumored to be looking at BioMarin for Roche.

　　This year, the stock columnist Michael cloth rush (MichaelBrush) according to RBC capital markets analyst Michael leaf (MichaelYee) comments, in MarketWatch online financial BioMarin listed as "one of the five big takeover candidate targets".In a survey conducted by EvercoreISI, BioMarin also became one of the top three major biopharmaceuticals companies to be bought.

　　Both market analysts cited the drugs for the sale of BioMarin and the candidate drugs being developed.Last year, BioMarin's sales reached $111.17 billion, up 26 percent from a year earlier.Two of the drugs already listed are growing at a staggering rate: the MorquioA syndrome enzyme replacement therapy vimizimin 2016 saw $354 million in net product revenue, up 55% from a year earlier.The first and only drug approved by the FDA, the drug Kuvan, was $348 million, up 46 percent from a year earlier.

　　At the r&d level, BioMarin is awaiting FDA approval for the treatment of battens' candidate drug Brineura, which the FDA is expected to make on April 27.The drug is also being approved by European regulators.In addition, in the second quarter of this year, the company is expected to apply to pegvaliase for a biologicals application for treatment of phenylketonuria.At the end of 2016, BioMarin vosoritide selected drugs used for the gnome symptom of 5 ~ 14 years old children begin Ⅲ period test, Ⅱ period test has achieved positive results.

　　3, BMS

　　The deal is more than $100 billion

　　BMS, the pharmaceutical giant, has at least caught the eye of two active investors, sparking speculation that it might be bought.Is one of the investor Carl Icahn (CarlC. Icahn), in February this year, the Wall Street journal said Icahn had bought shares in the BMS, to this, he neither confirm nor deny.A week later, he hired gm technology pioneer Richard Mulligan (RichardC. Mulligan) as a portfolio manager, suggests that he as a biological pharmaceutical active investors, to play a bigger role.

　　In addition, the end of last year, JanaPartners company become a shareholder in the BMS, as of December 31, the company has 3.9 million shares of BMS shares, worth $226 million, however, that stake is still far lower than 1%.According to Reuters, the figure will increase significantly this year, but still less than 1%.But JanaPartners' investment has paid off. In February, BMS nominated three new independent directors to its board.

　　On February 23, MotleyFool financial services analyst Todd Campbell (ToddCampbell) lists the five possible acquisition of BMS company: Amgen (Amgen), gilead sciences (GileadSciences), Pfizer (Pfizer), roche and sanofi-aventis (Sanofi).

　　StreetInsider lists gilead, Pfizer, roche and Novartis as possible acquirers.StreetInsider said trading could be worth as much as $120 billion.

　　4, Exelixis

　　Have a potential "bombshell"

　　In the biotech industry, the fortunes of companies are shifting fast.In 2015, Exelixis was also a loser on Wall Street, and just a year later, the company was on the right track to enter GEN's list of the top 10 companies in 2016.The shift also puts the company on another list of attractive m&a targets.

　　Exelixis last year in the development of drug Cabometyx has made a series of positive results, the drug in Ⅲ period test results can renal cell carcinoma (RCC) with novartis everolimus treatment drugs.Last April, Cabometyx was approved by the FDA, which was approved for sale in Europe in September.

　　Market analysts believe that gilead sciences is expected to become the potential acquirer Exelixis, although acquisition Exelixis is expensive, but it will boost geely's influence in the field of anti-tumor, also can let it has a potential "blockbuster" class antitumor drugs.

　　5, Genfit

　　NASH: "hot money"

　　Nonalcoholic fatty hepatitis (NASH) has become one of the most popular areas of biopharmaceutical industry, this situation will undoubtedly make focus on drugs for NASH Genfit outside wagging of mergers and acquisitions "prey".In early march, the rumors were even more rife as StreetInsider quoted unnamed sources as saying that novartis would almost reach a deal to buy Genfit.

　　The company's acquisition rumours began in December, when Genfit was said to be exploring the possibility of selling the company.Companies including sanofi, novartis and Shire may be interested in Genfit, the bloomberg news agency quoted anonymous sources as saying.

　　If Genfit is on the shelf, buyers may face stiff competition.Last year, allergan, claim to be the leader in the field of NASH, at that time, it announced plans to $1.695 billion deal to buy TobiraTherapeutics company, and to pay $50 million upfront fee AkarnaTherapeutics company.In January, the company's chief executive, John milligan, said the development of NASH would be a priority for the company in 2017.In addition, Pfizer has two drugs are in NASHⅠperiod development phase.

　　6, Incyte

　　The development of bright eye is strong

　　As sales of Jakafi continue to grow, there is talk of Incyte becoming a takeover target.Bone marrow fibrosis and polycythemia vera (PV) indications to help push the sales of Jakafi strong growth, the drug product net income of $853 million in 2016, up 42% from a year earlier.

　　In addition, Incyte has a strong r&d line.In January, the company announced that it would expand its clinical trial program to combine the epacadostat with Incyte and Keytruda, which is also known as Merck.For the combination of drugs used in four kinds of tumor Ⅲ phase of the trial is expected to start this year.The other is in the development of drug candidates with lilly baricitinib (EliLilly) cooperation, it is waiting for the FDA review, used to treat moderate to severe rheumatoid arthritis.The drug has been approved by European regulators.

　　RBC capital markets, the company general manager/advanced biotechnology, an analyst at west MiaoNi diss (SimosSimeonidis), according to the sales revenue is growing and developing lines of strong makes Incyte a reliable target.He added Incyte to the top five list of potential acquisition targets.

　　7,JunoTherapeutics

　　The plunge sent shares tumbling

　　A year ago, JunoTherapeutics was working alongside KitePharma and novartis in the development of the car-t immunotherapy drug.Later, the company in its main CAR - T drug candidates JCAR015 Ⅱ stage ROCKET tests of five participate type B cells of acute lymphocytic leukemia (ALL) patients died of brain edema.Now, JunoTherapeutics is far behind, and it will take at least a year to get its first immune-therapy drug to market.

　　On March 1, JunoTherapeutics terminated the development of JCAR015.Company will focus on below a rapid development process of CAR - T JCAR017 candidate drugs, in December, in patients with invasive non-hodgkin's lymphoma (NHL) in the test, it comes to some promising preliminary research data.

　　Since last July, Juno was the first to admit that there are three subjects death, since the company's share price has fallen by 45%, from $40.82 on July 7 last year fell to $22.48 this year on March 10.Market watchers say Juno's shares are expected to pick up this year, as the company has been rumored to be buying.

　　8, TheMedicinesCompany

　　Benefits of PCSK9 inhibitors

　　Sometimes, a biopharmaceutical company acquisition rumors, because it can benefit from competitors in related research, TheMedicinesCompany (TMC) that is the case.From Dec. 26 to Feb. 28, the company's stock rose 26 percent, to $150.25 from $119.

　　During this period, amgen from its FOURIER clinical trials have a positive study data, research has shown that PCSK9 inhibitors Repatha greatly reduce the risk of cardiovascular events.

　　Analytic personage points out, is also good for TMC amgen's the good news, because it is for companies to develop a cholesterol-lowering drugs inclisiran (formerly known as PCSK9si or ALN - PCSsc) is also aimed at PCSK9 targets.On November 15 last year, TMC and it announced that it from Ⅱ ORION - 1 got positive results in the study.

　　Famous Wall Street investment bank Jefferies has ranked TMC five this year may be one of the goals of the acquisition, "medical tech communication" jay silverman (JaySilverman) last fall also take the company as a takeover target.

　　9, NeurocrineBiosciences

　　Small business leaders

　　In a February 14 statement, the company's chief executive, KevinGorman, said 2017 would be a key year for the Neurocrine.The company's drug Ingrezza, which is used to treat late-onset dyskinesia, is awaiting FDA approval, and the FDA is expected to make its decision on April 11.

　　In January, Neurocrine was listed as a model for small biotech companies with several other companies.BMO capital markets analyst Ian suo get (M.I anSomaiya) said that if, as expected, trump's enterprises overseas money back tax proposal is passed, then Neurocrine may also become a large biopharmaceutical company targets.

　　10, Tesaro

　　The third PARP inhibitor is listed

　　In June last year, a Ⅲ phase trial of the positive results not only make Tesaro's share price has doubled, but also make it become a sought-after targets in investors.Since then, the debate over the possibilities of Tesaro has intensified.

　　In phase Ⅲ NOVA trials, the drug called Niraparib reached the primary end point of progression-free surial in patients with ovarian cancer.In November, Tesaro filed a new drug application for Niraparib to the FDA (NDA).A month later, the drug was approved by the FDA and approved by the listing.

　　Niraparib will be with the other two in the market compete PARP inhibitors of ovarian cancer, one of the only Lynparza AstraZeneca (AstraZeneca), another one is Rubraca ClovisOncology company, which in December 19, approved by the FDA.

　　In October last year, ubs analyst Alicia Yang (AlethiaYoung), and colleagues told investors that Tesaro has long been the media as a potential acquisition targets, the reason is that the market demand for assets in the later study stage of oncology has been high, particularly in the field of PARP inhibitors.

　　Previous post:None

　　Next post:The health and family planning commission and the TCM administration: the whole nation's basic medical facilities are equipped with equipment and promoted

　　TypeInfo: Industry News

　　Keywords for the information:Links: